Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $8.3 million.

  • Kiniksa Pharmaceuticals International's Other Non-Current Assets rose 553.93% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 553.93%. This contributed to the annual value of $10.3 million for FY2024, which is 114727.93% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Other Non-Current Assets is $8.3 million, which was up 553.93% from $8.2 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Other Non-Current Assets registered a high of $10.3 million during Q4 2024, and its lowest value of $827000.0 during Q4 2023.
  • For the 5-year period, Kiniksa Pharmaceuticals International's Other Non-Current Assets averaged around $5.9 million, with its median value being $5.8 million (2022).
  • In the last 5 years, Kiniksa Pharmaceuticals International's Other Non-Current Assets tumbled by 8580.01% in 2023 and then soared by 114727.93% in 2024.
  • Kiniksa Pharmaceuticals International's Other Non-Current Assets (Quarter) stood at $8.7 million in 2021, then tumbled by 33.21% to $5.8 million in 2022, then tumbled by 85.8% to $827000.0 in 2023, then surged by 1147.28% to $10.3 million in 2024, then fell by 19.65% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $8.2 million for Q2 2025, and $8.2 million during Q1 2025.